Standout Papers

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis 2006 2026 2012 2019 2.4k
  1. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis (2006)
    Chris H. Polman, Paul O’Connor et al. New England Journal of Medicine

Immediate Impact

15 from Science/Nature 70 standout
Sub-graph 1 of 17

Citing Papers

CAR T therapy beyond cancer: the evolution of a living drug
2023 StandoutNature
Macrophages as tools and targets in cancer therapy
2022 Standout
6 intermediate papers

Works of Martin Toal being referenced

A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies
2013
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2006 Standout

Author Peers

Author Last Decade Papers Cites
Martin Toal 357 960 222 1837 676 9 2.5k
Ernst-Wilhelm Radüe 471 671 224 1793 394 12 2.2k
Ludwig Kappos 247 908 195 1825 651 2 2.4k
A Wajgt 365 1236 231 2476 857 35 3.3k
Benjamin Brooks 206 453 168 1876 574 14 2.3k
Neena Sarkar 243 463 122 1451 1129 8 2.5k
L. P. Weiner 167 427 149 1677 490 11 2.1k
J. A. Cohen 216 522 189 2413 586 23 2.9k
Craig H. Smith 289 698 179 2317 1625 11 3.3k
Gavin Giovannoni 714 1393 369 3311 1033 17 4.4k
Sunil Agarwal 208 466 146 1789 1287 17 3.0k

All Works

Loading papers...

Rankless by CCL
2026